ClinicalTrialsFinder

BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia Clinical Trials in Shenzhen, Guangdong

1 recruitingShenzhen, Guangdong, China

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555